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Dr A. Kir1
doi:10.1016/j.jtcvs.2005.09.033bjective: Multidrug-resistant tuberculosis still continues to be a major health
roblem. Adjuvant surgical resection combined with antituberculous drug manage-
ent is the most favorable treatment modality for patients with multidrug-resistant
uberculosis. In this article we report the results of surgical resections we performed
uring the years 1993 through 2005.
ethods: We performed 81 lung resections in 79 patients with multidrug-resistant
uberculosis. All these patients had at least 2 months of medical therapy before
esection. Bronchial reinforcement was performed in 4 of the 81 operations. We
resent here the surgical results of the 81 procedures. Because 5 of 79 patients were
ost to follow-up, we provide the medical treatment results on 74 of the patients.
esults: During this period, we performed 4 completion pneumonectomies, 39 pneu-
onectomies, 7 lobectomies with segmentectomy, 30 lobectomies, and 1 segmentec-
omy. Operative mortality was 2.5% (2/81). Bronchopleural fistula developed in 4
4.9%) cases. Our overall cure rate was 94.5% (70/74). Relapse and treatment
ailure were 1.3% (1/74) and 1.3% (1/74), respectively. All but 5 patients are still
nder our follow-up.
onclusions: Surgical resection of patients with multidrug-resistant tuberculosis
ombined with chemotherapy provides a favorable outcome. Our results will need
o be validated more strongly by using randomized clinical trials that compare
urgical resection plus chemotherapy with chemotherapy alone.
rug resistance is still a major problem in the treatment of tuberculosis.
Resistance rates in Turkey are high because treatment approaches are often
inadequate, rates of treatment completion are low, and therapy is not
irectly observed.1
Surgical management of pulmonary tuberculosis emerged in the 19th century.
ost interventions were collapse therapies, such as thoracoplasty, plombage, arti-
cial pneumothorax, pneumoperitoneum, and phrenic nerve crush. The aim of these
nterventions was to deprive aerobic mycobacteria in lung cavities of oxygen.
owever, until the 1940s, the results of surgical resectional approaches were
nsatisfactory. With the advent of chemotherapeutic agents and improvements in
urgical techniques, anesthetics, and intensive care facilities, resectional surgical
nterventions became safer. However, management with multidrug agents, including
ifampin [INN: rifampicin], has decreased the resectional surgery rate.2 After the
980s, epidemics of AIDS, immigration, intravenous drug abuse, deterioration in health
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TSare systems, delays in diagnosis, and inappropriate therapies
ed to an increase in tuberculosis cases and in multidrug-
esistant disease.3 This led most physicians to offer resectional
perations as an adjuvant treatment.4 In this article we update
ur previous experience in the surgical treatment of multidrug-
esistant tuberculosis (MDR-TB).5
aterials and Methods
his study included 79 HIV-negative patients with MDR-TB who
nderwent 81 adjuvant resectional surgery procedures, each per-
ormed by the same surgeon (A.K.), between 1993 and 2005 in the
üreyyapasa Center for Chest Diseases and Thoracic Surgery, the
ajor referral center for pulmonary diseases in Turkey. Of these
atients, 17 were female and 62 were male. The mean age was 37.6
ears, ranging between 16 and 65 years.
Chest radiographs revealed bilateral lesions in 27 (33.3%)
ases, with a preponderance of cavities on one side. Resistance to
t least isoniazid and rifampin was regarded as multidrug resis-
ance. All the patients had been receiving antituberculosis therapy
ith various drugs for between 1 and 19 years. MDR-TB treatment
rotocols for all patients were designed by using at least 4 active
rugs (average, 5 drugs; range, 4-7 drugs). In all cases one paren-
eral drug was used, either amikacin or kanamycin, or, if resistance
as found to these, capreomycin.
The average preoperative treatment duration was 4.01 months
range, 2-8 months). Preoperative studies routinely included chest
adiography, computed tomographic chest scans, pulmonary func-
ion tests, arterial blood gas analysis, and, if necessary, a quanti-
ative perfusion scan. We performed bronchoscopic biopsies to
ule out tuberculous bronchitis. None of the patients were cachec-
ic, and all exhibited an appropriate nutritional status. Preopera-
ively, 13 (16%) patients had positive acid-fast bacilli in the
putum, and in 12 patients (14.8%) culture of mycobacterium
uberculosis was positive.
Two patients were operated on twice. In the first patient, who
resented with bilateral lesions, we performed upper lobectomies.
e operated on the second patient to perform a completion pneu-
onectomy because he relapsed 4 years after we performed a left
ung upper lobectomy with a lower lobe superior segmentectomy.
our patients were operated on at other hospitals before admission
o our hospital. Of these, one had a right upper lobectomy because
f tuberculosis, and another had a right upper lobectomy for a
arcinoid tumor. We performed right completion pneumonecto-
ies on both these patients. Of the remaining 2 patients, one had
ad a standard thoracoplasty for cavitary tuberculosis, and we
erformed a left pneumonectomy. The final patient had had a left
pper lobectomy because of MDR-TB but had relapsed 2 years later;
n this patient we performed a left completion pneumonectomy.
Surgical resection was considered for all the patients after 2
onths of medical treatment. The selection of patients for surgical
Abbreviations and Acronyms
BPF  bronchopleural fistula
MDR-TBmultidrug-resistant tuberculosisntervention was made according to the criteria recommended by p
94 The Journal of Thoracic and Cardiovascular Surgery ● Marcseman and associates,4 which included (1) drug resistance with a
igh probability of failure or relapse; (2) sufficiently localized
isease providing the resection of great preponderance of radio-
raphically visible disease, leaving an adequate cardiopulmonary
apacity; and (3) availability of adequate drug efficacy to provide
apid healing of the bronchial stump.
Operations were performed after achievement of general anes-
hesia with the use of a double-lumen endobronchial tube. After
nduction of anesthesia, we performed a serratus-sparing postero-
ateral thoracotomy. Either an intrapleural or an extrapleural dis-
ection was performed, depending on the extent of pleural adhe-
ions. Eighty-one pulmonary resections were performed (Table 1).
The bronchus was divided and closed with a stapler (n 48) or
utures (n  33). For suturing, we used Ethibond (Johnson &
ohnson, New Brunswick, NJ) until 1997 and then polyglactin. In
stapled pneumonectomies the bronchial stump was reinforced
ith intercostal muscle, pericardial fat pad (n  2), and medias-
inal pleura, respectively. We used a linear cutter during lobecto-
ies when incomplete fissures were present. After the operations,
he patients were maintained on multidrug regimens, which were
enerally the same as their preoperative regimens.
Operative mortality included all deaths clearly related to the
perations, regardless of the postoperative interval. Definitions of
utcomes are based on the definitions of the World Health Orga-
ization6: relapse is recurrence of a positive smear or culture after
cure; treatment failure is persistence of positive smears or
ultures, despite treatment for at least 18 or 24 months; probable
ure is negative smears and cultures throughout treatment for at
east 6 months; and cure is negative smears and cultures through-
ut at least 18 months of treatment (or 24 months in the absence of
rst-line drugs).
esults
ostoperative sputum was positive in 2 (2.5%) cases, and
ultures were positive in 3 (3.7%) cases. In one patient a
reoperative bronchoscopic bronchial biopsy revealed tu-
erculous bronchitis. In this case we postponed surgical
ntervention for 2 months until a repeat bronchoscopy proved
egative for tuberculosis and continued medical treatment.
fter the repeat bronchoscopy was negative for tuberculo-
is, he underwent surgical intervention.
Thirty-four right-side and 47 left-side operations were
ABLE 1. Types of pulmonary resection
rocedure Right Left Total
ompletion pneumonectomy 2 2 4
neumonectomy 11 28 39
pper and middle lobectomy 2 0 2
pper lobectomy with segmentectomy* 3 4 7
pper lobectomy 12 11 23
ower lobectomy 4 1 5
egmentectomy 0 1 1
otal 34 47 81
Upper lobectomy with resection of superior segment of the lower lobe.erformed. We performed 4 completion pneumonectomies,
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G
TS9 pneumonectomies, 7 lobectomies with segmentectomy,
0 lobectomies, and 1 segmentectomy. Operative mortality
as 2.5% (2/81). One patient with postpneumonectomic
ronchopleural fistula (BPF) died 3 months after surgical
ntervention of respiratory failure. The other patient died
ecause of low cardiac output syndrome on the first day
fter surgical intervention.
Three left pneumonectomies and 2 right pneumonec-
omies required revision in the first 48 hours after inter-
ention because of hemorrhage and hematoma. At revi-
ions, the exact source of hemorrhage could not be
etected. BPF developed in 4 (4.9%) patients, 2 of whom
ad had left pneumonectomies, one of whom had a right
neumonectomy, and one of whom had a right upper
obectomy with lower lobe superior segmentectomy. The
ate of BPF in pneumonectomy cases was 7% (3/43). All
f these patients had negative sputum results. In these
ases the bronchus was divided with a stapler in 1 and
ith sutures in 3. In the last 43 resections, only 1 (2.3%)
PF presented. In other words, in this series in the last 7
ears, only one BPF occurred. Of the 4 patients who
resented with BPF, 1 patient did not accept an open
indow procedure and was discharged with an open tube
rainage. He died in the postoperative third month be-
ause of respiratory failure. In the second case the fistula
as 2 mm in diameter. The drainage and modified Clagett
ethod resulted in a favorable outcome for this patient.
n a third patient with BPF after right pneumonectomy,
e performed thoracoplasty protecting the first rib. In the
ourth patient BPF occurred after a lobectomy with seg-
entectomy, and this was treated by performing an apical
imited thoracoplasty. Thirty-one patients had a total of
5 complications. Twenty patients had a major pulmo-
ary complication (Table 2). Retreatment protocols re-
ulted in negative cultures and smears in all patients
xcept 1, with an average duration of 4 months (range,
-6 months). Of the 79 patients, 5 were lost to follow-up,
eaving 74. Of these, 67 (90.5%) were cured, and 3
4.0%) were probably cured. The overall treatment suc-
ess was 94.5% (70/74). Relapse occurred in 1 of 74
atients, and this patient died of massive hemoptysis 3
ears after surgical intervention. Treatment failure oc-
ABLE 2. Postoperative major pulmonary complications
omplications No. of patients (%)
ronchopleural fistula with empyema 4 (4.9)
pace problem 2 (2.5)
rolonged air leak 7 (8.6)
telectasis 2 (2.5)
emorrhage and hematoma 5 (6.2)urred in 1 of 74 patients. c
The Journal of Thoraciciscussion
he recent emergence of tubercle bacilli resistant to both
soniazid and rifampin, which are the most potent antitu-
erculous drugs, is an emerging global problem.7,8 Surgical
ndications for MDR-TB are persistent cavitary disease and
estroyed lung and lobe. MDR-TB and its complications are
urrently the main indicators for surgical intervention in
ulmonary tuberculosis.9 The stated reasons for resection in
atients with cavitary disease are the difficulty of antibiotic
enetration and the large number of organisms contained
ithin cavities. Because of this, it is important to resect all
avitary disease and destroyed lung without leaving grossly
iseased lung behind.9
Surgical resection was considered after 2 months of
reatment for all patients.1 In these series we performed
ither intrapleural or extrapleural dissection, depending on
he extent of pleural adhesions. We believe that local ex-
rapleural dissection might be reserved for patients with
pical or other pleural adhesions.5 This approach is also
ecommended by others.9
The postoperative mortality and morbidity rate for pul-
onary tuberculosis is decreasing. This is largely because
f proper selection of the patient, developments in anesthe-
ia techniques, the introduction of stapling devices, and the
ffective postoperative use of antituberculosis agents post-
peratively.10 The mortality rate of MDR-TB after resec-
ional operations ranged from 0% to 3.3% in the most recent
eries.9,11-13 However, in the early studies the mortality rate
as as high as 11%.4 Meanwhile, recently reported mortal-
ty rates are comparable with the mortality rate we achieved
2.4%). In our first article, which was based on the first 27
ases of our present study, the 30-day mortality rate was
ero.5 However, in this updated series the overall mortality
ate was 2.5% (2/81 cases). This increase in mortality rates
etween the cases presented in the first study and this one
ould be due to a better patient selection for surgical inter-
ention in the earlier stages of this study.
Major complications were reported in approximately
5% and included empyema, BPF, postoperative bleeding,
nd respiratory failure. In previous series the BPF rate was
etween 25% and 40%,12,14-17 but in recently published
tudies the BPF rate was less than 6%.9,11-13 Some authors
ecommend using muscle flap to reinforce the bronchial
tump and reported a low BPF incidence rate.18 Some report
hat nondevascularizing bronchial dissection and avoidance
f electrical diathermy is important for the prevention of
PF.13 Although patients with positive sputum results were
eported to be at high risk for BPF development,12 we did
ot see any BPF in our 13 patients with positive sputum
esults. In this study the BPF rate was 4.9%. However, in
ur last 43 resections, which were performed in the last 7
ears, we had only one occurrence of BPF (1/43 [2.3%]
ases). We attribute this decrease to our increased surgical
and Cardiovascular Surgery ● Volume 131, Number 3 695
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G
TSxperience. In addition, although we do not use bronchial
tump reinforcement, our BPF rate is comparable with those
f other studies that use extrathoracic muscle flaps to rein-
orce the bronchial stump.9,11 We think that handling the
ronchus is the key point in the avoidance of BPF. In our
tudy we did not routinely reinforce the bronchial stump,
xcept in 4 cases. We think that reinforcement is not nec-
ssary because it requires excessive manipulation and un-
ecessary placement of sutures to the bronchus. Although
PF occurred in patients without reinforcement, the number
s too small to make a healthy assessment and compare with
he 4 cases with bronchial stump reinforcement. In addition,
uring the last 7 years, we observed only one BPF among 43
ases.
Our results show that surgical resection combined with
hemotherapy in cases of MDR-TB provides a favorable
utcome. Nevertheless, this result needs to be validated
ore strongly by randomized clinical trials that compare
urgical resection plus chemotherapy with chemotherapy
lone.
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